Our lab is currently evaluating the therapeutic effects of troriluzole plus anti-PD-1 in our Grm1 driven spontaneous melanoma prone mouse model, this combinatorial approach is also under clinical investigation in melanoma patients with brain metastases (NCT04899921). The gene discussed is GRM1; the disease is melanoma.